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Abstract
Background: Nrf2 is a key transcriptional regulator of a battery of genes that facilitate phase II/III drug metabolism
and defence against oxidative stress. Nrf2 is largely regulated by Keap1, which directs Nrf2 for proteasomal
degradation. The Nrf2/Keap1 system is dysregulated in lung, head and neck, and breast cancers and this affects
cellular proliferation and response to therapy. Here, we have investigated the integrity of the Nrf2/Keap1 system in
pancreatic cancer.
Results: Keap1, Nrf2 and the Nrf2 target genes AKR1c1 and GCLC were detected in a panel of five pancreatic
cancer cell lines. Mutation analysis of NRF2 exon 2 and KEAP1 exons 2-6 in these cell lines identified no mutations
in NRF2 and only synonomous mutations in KEAP1. RNAi depletion of Nrf2 caused a decrease in the proliferation of
Suit-2, MiaPaca-2 and FAMPAC cells and enhanced sensitivity to gemcitabine (Suit-2), 5-flurouracil (FAMPAC),
cisplatin (Suit-2 and FAMPAC) and gamma radiation (Suit-2). The expression of Nrf2 and Keap1 was also analysed in
pancreatic ductal adenocarcinomas (n = 66 and 57, respectively) and matching normal benign epithelium (n = 21
cases). Whilst no significant correlation was seen between the expression levels of Keap1 and Nrf2 in the tumors,
interestingly, Nrf2 staining was significantly greater in the cytoplasm of tumors compared to benign ducts
(P < 0.001).
Conclusions: Expression of Nrf2 is up-regulated in pancreatic cancer cell lines and ductal adenocarcinomas. This
may reflect a greater intrinsic capacity of these cells to respond to stress signals and resist chemotherapeutic
interventions. Nrf2 also appears to support proliferation in certain pancreatic adenocarinomas. Therefore, strategies
to pharmacologically manipulate the levels and/or activity of Nrf2 may have the potential to reduce pancreatic
tumor growth, and increase sensitivity to therapeutics.
Introduction
Pancreatic cancer is a leading cause of cancer-related
deaths in the US and in Europe [1]. It carries a dismal
prognosis, which is attributed in part to a high level of
resistance to chemotherapeutic drugs [2]. For the vast
majority of patients, the disease is at an advanced stage
when diagnosed, and chemotherapy in the form of gem-
citabine is the standard of care. Recent evidence sug-
gests that combining gemcitabine with other agents,
such as erlotinib or capecitabine, may provide greater
benefit [3,4]. A small minority of patients (10-20%) can
avail of potentially curative surgery, and for these
patients the outlook is better [5,6]. Nonetheless, the
overall survival rate of pancreatic cancer patients
remains very poor. The mechanisms of drug uptake,
DNA repair and apoptosis have all been proposed to
contribute to the resistance of pancreatic cancer cells to
chemotherapy [7]. Moreover, a recent study using a
genetically-engineered mouse model of pancreatic can-
cer revealed that treatment failure could be attributed to
inefficient gemcitabine delivery to tumor cells, likely due
to poor vascularisation of the tumor [8]. A deeper
understanding of the mechanisms of chemotherapy
resistance in pancreatic cancer cells may allow the
development of more targeted treatment options.
The Nuclear factor erythroid 2-related factor 2 (Nrf2)/
Kelch-like ECH-associated protein 1 (Keap1) system
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lian cells can sense and adapt to chemical and oxidative
stresses [9-11]. Normally, Keap1 targets Nrf2 for ubiqui-
tylation, leading to its proteasomal degradation [12]. In
response to chemical or oxidative stress, the interaction
between Nrf2 and Keap1 is perturbed, resulting in the
stabilization and nuclear accumulation of Nrf2 [11,13].
Nrf2 localised in the nucleus interacts with antioxidant
response elements in the promoter regions of a plethora
of genes coding for phase 2 detoxifying enzymes (e.g.
glutathione-S-transferases and NAD(P)H quinone oxi-
doreductase), antioxidant proteins (e.g. glutathione syn-
thetic enzymes) and transporters (e.g. ABCC2, ABCC3,
ABCG2 and xc
- subunit) [14-18].
Elevated Nrf2 levels have been observed in head and
neck [19], gall bladder [20] and lung cancer [21], and
evidence indicates that a dysregulated Nrf2/Keap1 sys-
tem may protect against the deleterious effects of oxida-
tive stress, whilst also conferring properties of enhanced
cellular proliferation and a drug-resistant phenotype, in
certain cancers [20,22,23], effectively acting as a double-
edged sword [22]. Here we have investigated the integ-
rity of the Nrf2/Keap1 system in pancreatic cancer.
Results
Delineation of the Nrf2/Keap1 system in five pancreatic
cancer cell lines
In order to investigate the integrity of the Nrf2/Keap1
system in pancreatic cancer, we first examined the pro-
tein expression levels of Keap1 and Nrf2 across a panel
of five human pancreatic cancer cell lines. In Miapaca-2,
Panc-1, FAMPAC and Paca-2 cell lines, the basal
expression levels of Keap1 were high, whilst the levels of
Nrf2 were below the limit of detection. Conversely, the
Suit-2 cell line had low levels of Keap1, and detectable
levels of Nrf2, under basal conditions (Figure 1A and
1 B ) .I na l lc e l ll i n e st h ep r o teasome inhibitor MG132
caused the stabilization of Nrf2 (Figure 1B), indicating
that the classical mechanism of Nrf2 degradation exists
in these cells.
To examine the correlation between the protein
expression of Nrf2 or Keap1 and the abundance of their
respective mRNA amongst the panel of cell lines, the
copy numbers of Nrf2 and Keap1 mRNA were quanti-
fied by RTPCR (Additional file 1, Figure S1A). Signifi-
cantly higher levels of Keap1 mRNA were detected in
FAMPAC cells compared to MiaPaca-2 and Suit-2.
These data indicate a correlation between Keap1 mRNA
and protein levels in FAMPAC (high levels of Keap1)
and Suit-2 (low levels of Keap1) cells, but reveal a lack
of correlation in MiaPaca-2 cells (low Keap1 mRNA and
high Keap1 protein) (Figure 1A and Additional file 1,
Figure S1A). No significant differences were detected in
the mRNA copy number of Nrf2 between the five cell
lines (Additional file 1, Figure S1B), indicating that post-
translational factors underpin the different levels of
expression of Nrf2 protein across this panel of cells.
To relate the protein expression levels of Nrf2 with its
basal activity, we examined the protein levels of two Nrf2
target genes, AKR1c1 and GCLC, as well as the product
of GCLC activity, glutathione (GSH). FAMPAC cells
expressed low basal AKR1c1 and GCLC (Figure 1C), cor-
relating with their high Keap1 and low Nrf2 expression
levels. Suit-2 cells expressed high levels of AKR1c1 and
GCLC (Figure 1C), correlating with their low Keap1 and
high Nrf2 expression levels. Additionally, total cellular
GSH levels were significantly lower in FAMPAC cells
compared to Suit-2 cells (Figure 1D). Interestingly, both
MiaPaca-2 and Panc-1 cells expressed high levels of
AKR1c1, and the Paca-2 cells expressed high levels of
GCLC (Figure 1C), further indicating a lack of correlation
between the expression levels of Keap1, Nrf2 and Nrf2
target genes, and as such a dysregulation of the Nrf2/
Keap1 system, in these cell lines.
In order to explore the potential mechanisms underly-
ing the dysregulation of the Nrf2/Keap1 system in the
pancreatic cancer cell line panel, we sequenced the pro-
tein-coding exons 2-6 of the KEAP1 gene and exon 2 of
NRF2, which have been shown to contain functionally
relevant SNPs in other cancer types [24]. Heterozygotic
KEAP1 gene mutations were observed in the MiaPaca-2
and Panc-1 cells (data not shown), although all were
synonomous. NRF2 exon 2 was wild-type in all the cell
lines (data not shown). Additionally, we analyzed the
publicly-available transcript sequencing data from 24
pancreatic cancer samples, described by Jones et al [25].
Neither non-synonomous mutations nor copy number
alterations were detected within the NRF2 or KEAP1
genes in these tumors. Taken together, these results
indicate that post-translational factors contribute to the
dysregulation of the Nrf2/Keap1 system in a subset of
pancreatic cancer cell lines.
Functional examination of the Nrf2/Keap1 system in
pancreatic cancer cell lines
We next explored the function of the Nrf2/Keap1 sys-
tem in three pancreatic cancer cell lines showing
extremes of Nrf2/Keap1 expression; Suit-2 (lowest
Keap1 and highest Nrf2), FAMPAC (highest Keap1 and
lowest Nrf2), and MiaPaca-2 (high Keap1 with a lack of
correlation between levels of Nrf2 and expression of
Nrf2 target genes) (Figure 1). siRNA depletion of Nrf2
caused a decrease in the expression levels of the Nrf2-
regulated proteins GCLC and AKR1c1 in all three cell
lines (Figure 2B and Additional file 2, Figure S2). Total
GSH levels were significantly decreased, 96 h following
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lines (Figure 2C). Significant downregulation of the Nrf2
target genes HO-1, MRP5 and BCRP was also observed
in the Suit-2 cells following siRNA depletion of Nrf2
(Additional file 3, Figure S3). There were no significant
changes in GSH following siRNA depletion of Nrf2 in
the FAMPAC cell line (Figure 2C), which exhibits low
basal Nrf2 expression and activity (Figure 1). Impor-
tantly, siRNA depletion of Keap1 resulted in an increase
in the protein levels of Nrf2 and its target genes
AKR1c1 and GCLC in both FAMPAC and Miapaca-2
cells (Additional file 4, Figure S4). These data suggest
that, even in pancreatic cell lines in which the Nrf2/
Keap1 system appears to be dysregulated, the pathway
does retain its functional integrity.
Nrf2 regulates pancreatic cancer cell proliferation
In light of recent reports that Nrf2 regulates cancer cell
proliferation [22,23], and given that the Nrf2/Keap1 sys-
tem is functional in Suit-2, Miapaca-2 and FAMPAC
pancreatic cancer cells, we examined the role of Nrf2 in
determining the rate of proliferation of these cells.
siRNA depletion of Nrf2 in Suit-2 cells was accompa-
nied by a > 60% decrease in viability compared to cells
transfected with scrambled siRNA (Figure 3A). Mia-
Paca-2 and FAMPAC cells, which display intermediate
and low levels of Nrf2 activity, respectively, exhibited
intermediate or small decreases in viability following
depletion of Nrf2 (Figure 3A). Trypan blue staining of
cells over a 120 h timecourse revealed that siNrf2 deple-
tion of Nrf2 caused Suit-2, MiaPaca-2 and FAMPAC
Figure 1 Basal expression levels of Keap1, Nrf2 and Nrf2-regulated genes GCLC and AKR1c1 and GSH amongst a panel of pancreatic
cancer cell lines. A, Immunoblot detection of basal Keap1 protein in MiaPaca-2, Panc-1, FAMPAC, Paca-2 and Suit-2 cells. B, Immunoblot
detection of basal Nrf2 in cells untreated or treated with the proteosome inhibitor MG132 (10 μM) for 2 h in order to visualize Nrf2 protein. The
band labelled ‘non-specific’ was not depleted following transfection with 10 nM Nrf2-targeting siRNA Nrf2 (data not shown). Beta actin was used
as a reference control for blots A and B. C, Immunoblot detection of basal GCLC and AKR1c1. D, Total basal glutathione levels. * = P < 0.05,** =
P < 0.01,*** = P < 0.001.
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transfected with non-targeting scrambled siRNA (Figure
3B). The effect was most pronounced in Suit-2 cells,
which express the highest basal level of Nrf2, and least
pronounced in FAMPAC cells, which express the lowest
basal level of the transcription factor (Figure 3B). Impor-
tantly, siRNA depletion of Keap1 significantly increased
t h er a t eo fp r o l i f e r a t i o no fF A M P A Cc e l l s ,w h i c hh a v e
high Keap1 protein levels and very low Nrf2 activity
(Additional file 5, Figure S5). These results indicate that
Nrf2, at least partly, contributes to the rate of prolifera-
tion of pancreatic cancer cells.
In order to further define the role of Nrf2 in deter-
mining the proliferation rate of pancreatic cancer cells,
propidium iodide staining was employed to examine the
cell cycle status of Suit-2 and FAMPAC (i.e. cells that
exhibit high and low basal levels of Nrf2 activity, respec-
tively) following siRNA depletion of Nrf2. In Suit-2 cells
transfected with scrambled siRNA for 72 h, an approxi-
mately equal number of cells were found in each stage
of the cell cycle (Figure 4A). In contrast, Suit-2 cells
treated with Nrf2 siRNA for the same period of time
showed a significant increase in the proportion of cells
in G1 phase (Figure 4A). In contrast, the number of
FAMPAC cells in the G1 phase did not differ following
siRNA depletion of Nrf2 (Figure 4A). These results sug-
gest that Nrf2 is important for progression through the
G1 phase of the cell cycle in Suit-2 cells, which express
high levels of the protein. However, in FAMPAC cells,
in which Nrf2 is constitutively repressed, proliferation is
not constrained by the requirement for Nrf2, and hence
Nrf2 depletion has little effect on the rate of progression
Figure 2 Response of Nrf2-target genes to siRNA depletion of Nrf2 in FAMPAC, MiaPaca-2 and Suit-2 pancreatic cancer cells. Cells were
transfected with 10 nM Nrf2-targeting siRNA, or Stealth RNAi control, for 96 h. A, qRTPCR analysis of relative Nrf2 mRNA expression. GAPDH was
used as a reference control. B, Immunoblot detection of GCLC and AKR1c1 in three parallel experiments. Beta-actin is used as reference control.
C, Total glutathione levels. Data are the means ± S.D. of four discrete experiments. * = P < 0.05,** = P < 0.01.
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proliferation (Figure 3B).
In order to investigate whether Nrf2 expression
altered the apoptotic status of the Suit-2 and FAMPAC
cell lines, annexin-5/propidium iodide dual staining was
performed 72 h following transfection with Nrf2-target-
ing siRNA. There was no evidence of apoptosis in the
Suit-2 or FAMPAC cell lines (Figure 4C), which may
reflect the late time point at which the assay was per-
formed or that neither cell line expresses functional p53
protein [26,27]. Taken together, these results suggest
that Nrf2 regulates the rate of proliferation and cell
cycle progression in pancreatic cancer cells exhibiting
high basal levels and activity of Nrf2, such as Suit-2.
Nrf2 enhances chemo- and radioresistance in pancreatic
cancer cells
Nrf2 has been shown to, at least partly, determine the
sensitivity of cancer cells to chemotherapeutic agents
[20-23]. We therefore examined of the role of Nrf2 in
determining the sensitivity of Suit-2 and FAMPAC cells
to the chemotherapeutic agents gemcitabine, 5-FU and
cisplatin, as well as to gamma irradiation. siRNA deple-
tion of Nrf2 elicited a significant increase in sensitivity to
gemcitabine (2.6 fold; Figure 5A) and cisplatin (3.4 fold;
Figure 5C), but had no discernable effect on sensitivity to
5-FU (Figure 5B), in Suit-2 cells. In FAMPAC cells,
siRNA depletion of Nrf2 had no effect on sensitivity to
gemcitabine (Figure 5A), but did cause a significant
increase in sensitivity to 5-FU (2.3 fold; Figure 5B) and
cisplatin (3.1 fold; Figure 5C). Depletion of Nrf2 caused a
decrease in the viability of Suit-2 and FAMPAC cells fol-
lowing exposure to gamma radiation (Figure 5D),
although the effect on FAMPAC cells was not statistically
significant. Taken together, these results indicate that
Nrf2 plays a role in determining the sensitivity of pan-
creatic cancer cells to chemotherapeutic agents.
Expression of Nrf2 is increased in pancreatic cancer
tumors
Following our delineation of the Nrf2/Keap1 system in
pancreatic cancer cell lines, we examined the expression
Figure 3 Effect of siRNA depletion of Nrf2 on proliferation of FAMPAC, MiaPaca-2 and Suit-2 pancreatic cancer cells. Cells were
transfected with 10 nM Nrf2-targeting siRNA, or Stealth RNAi control, for up to 120 h. A, Cell survival was measured at 120 h using the MTS test.
Data is shown as cell viability versus Stealth RNAi control. B, Cell numbers were quantified at the indicated time points using Trypan blue
staining. Data are the means ± S.D. of four discrete experiments. ** = P < 0.01,*** = P < 0.001.
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human pancreatic tumor tissues, using immunohisto-
chemistry. Cytoplasmic Nrf2 was detected in 93% (n =
53/57) of tumors, with strong staining (score > 45, the
optimum cut-off value for discriminating between strong
and weak staining was determined by the receiver oper-
ating characteristic curve (ROC curve)) observed in 84%
of cases (n = 48/57). By contrast, whilst cytoplasmic
Nrf2 staining was observed in a high percentage of
matching benign ducts (86%, n = 18/21), staining was
predominantly weak (66%; 14/21) with strong staining
observed in 19% (4/21) of cases only. The increased
cytoplasmic Nrf2 expression in tumors was statistically
significant (P < 0.0001, Mann-Whitney U-test).
Although 53% (n = 30/57) of patients had detectable
Nrf2 in the nuclear compartment of tumor cells, no dif-
ference in nuclear Nrf2 levels was observed between
tumor and benign epithelium (P = 0.44, Mann-Whitney
U-test), In order to appraise the overall Nrf2 levels
(cytoplasmic and nuclear) in tumors, compared to their
matched benign tissue, Nrf2 stained tissues were cate-
gorised into four distinct groups: i) high cytoplasmic
Nrf2 and high nuclear Nrf2 (H
C/H
N), ii) high cytoplas-
mic Nrf2 and low nuclear Nrf2 (H
C/L
N), iii) low cyto-
plasmic Nrf2 and high nuclear Nrf2 (L
C/H
N) and iv) low
cytoplasmic Nrf2 and low nuclear Nrf2 (L
C/L
N). Nota-
bly, the majority of the tumors (47.6%; 10/21) expressed
high cytoplasmic Nrf2 and high nuclear Nrf2 (H
C/H
N),
whereas the majority of the benign ducts (47.6%; 10/21)
expressed low cytoplasmic Nrf2 and low nuclear Nrf2
(L
C/L
N) (Additional file 6, Figure S6).
Keap1 was detected in 30% of tumors only (n = 19/
63), and found exclusively in the cytoplasm (Figure 6E-
H). Keap1 was not detected in benign ductal epithelium
(n = 0/21). There was no correlation between the pre-
sence of Keap1 and the levels of either cytosolic or
nuclear Nrf2 in the pancreatic tumors (P = 0.47 and P =
0.86, respectively, Mann-Whitney U-test), indicating that
the dysregulated Nrf2/Keap1 phenotype observed in
some pancreatic cancer cell lines is also apparent in pri-
mary tumors. We found no significant association
between the levels of Nrf2 (cytoplasmic or nuclear) or
Keap1 in the pancreatic tumors and various clinico-
pathological parameters, (Additional file 7 &8, Tables S1
& S2).
Discussion
Nrf2 controls a battery of genes that protect cells from
chemical and oxidative stresses, and a number of Nrf2-
regulated genes have been reported to be overexpressed
Figure 4 Effect of siRNA depletion of Nrf2 on cell cycle progression and apoptosis status of Suit-2 and FAMPAC pancreatic cancer
cells. Cells were transfected with 10 nM Nrf2-targeting siRNA, or Stealth RNAi control, for 72 h. A, Flow cytometric analysis of cell cycle status in
propidium iodide stained cells. Data are the means ± S.D of four discrete experiments. * = P < 0.05. B, Micrographs depicting cells analysed in A.
C, Flow cytometric analysis of apoptotic status in Annexin 5/propidium iodide stained cells.
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Page 6 of 13Figure 5 Effect of siRNA depletion of Nrf2 on sensitivity of Suit-2 and FAMPAC pancreatic cancer cells to chemo- and radiotherapies.
Cells were transfected with 10 nM Nrf2-targeting siRNA, or Stealth RNAi control, for 48 h followed by exposure to gemcitabine (A), 5 flurouracil
(5-FU) (B), cisplatin (C) or gamma radiation (D) for 72 h, at the indicated concentrations. Cell viability was measured using the MTS assay. Graphs
represent data as a surviving fraction versus non-drug treated Stealth RNAi control transfected cells. IC50 values are expressed as μM. Data are
the means ± S.D. of four discrete experiments. * = P < 0.05,** = P < 0.01,*** = P < 0.001.
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demonstrated a lack of consistent correlation between
the basal expression levels of Keap1 and Nrf2 mRNA
and protein, together with the activity of Nrf2, between
pancreatic cancer cell lines, indicating that the Nrf2/
Keap1 system may be dysregulated in pancreatic cancer.
In contrast to other cancers, we found no evidence for
the existence of non-synonmous mutations in NRF2 or
KEAP1 in our panel of cell lines, nor in publicly-
available SAGE gene expression data from a panel of 24
advanced pancreatic adenocarcinomas [25]. However,
the latter analysis revealed that in > 75% of the cancers,
Nrf2 expression is at least 10-fold higher than in normal
pancreatic ductal cells. A similar increase in Nrf2 pro-
tein expression in malignant, compared to benign,
epithelium has been recently reported in a smaller
cohort of pancreatic adenocarcinoma patients and non-
matching controls [32]. Amongst our human pancreatic
Figure 6 Immunohistochemical analysis of Nrf2 and Keap1 in pancreatic tissues.Aa n dB ,P a n c r e a t i cc a n c e rt i s s u es h o w i n gs t r o n ga n d
weak Nrf2 levels, respectively. E and F, Pancreatic cancer tissue showing Keap1 expression. C and G, Pancreatic cancer tissue showing absence of
detectable Nrf2 and Keap1, respectively. D and H, Benign pancreatic tissue showing Nrf2 expression in ductal cells and acinar cells (D) and
absence of Keap1 in ductal cells, with positive islet cells (H). Scale bars = 50 μm.
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plasmic Nrf2 and high nuclear Nrf2, whereas the major-
ity of benign ducts expressed low cytoplasmic Nrf2 and
low nuclear Nrf2. The increased cytoplasmic Nrf2 levels
may reflect a greater intrinsic capacity of the tumor cells
to respond to stress signals and resist chemotherapeutic
agents. It is possible that the high expression of Nrf2 in
the pancreatic adenocarcin o m at i s s u e si sd u et ot h e
elevated expression of proteins that can increase the stabi-
lity of Nrf2, such as Sequestosome-1 [33,34] and Prothy-
mosin-a [35], by competing with Nrf2 for the Keap1
binding site. Other possible mechanisms include: Keap1
down-regulation via promoter methylation, which has
been described in lung cancer [36], transcriptional
up-regulation of the NRF2 gene (which although not iden-
tified here in the pancreatic cancer cell lines, may never-
theless play a role in the tumors), dysregulation of Nrf2
ubiquitylation and proteasomal degradation, and stabiliza-
tion of Nrf2 as a result of chronic oxidative stress. The
contribution of these and other factors to the relatively
high expression levels of Nrf2 in pancreatic cancer cells
should be further examined in order to better understand
the contribution of Nrf2 levels to cellular phenotype.
Although we have demonstrated that cytoplasmic
levels of Nrf2 are significantly elevated in pancreatic
tumors compared to matching benign ducts, nuclear
levels of Nrf2 do not appear to differ between the two
tissue types. It is well established that oxidative stress
represents a primary signal that causes cytoplasmic Nrf2
to accumulate within the nucleus [11]. Although cancer
cells generally have high levels of ROS due to uncon-
trolled cellular proliferation [37], these oxidative stress
signals may only be transiently present. In addition, the
primary tumor samples used in this study were obtained
by surgical resection prior to chemotherapy/radiation
treatment, further restricting their exposure to oxidative
stress. It is possible that the elevated cytoplasmic Nrf2
population observed in pancreatic cancer cells repre-
sents an increased capacity to sense and respond to per-
turbations in the cellular redox environment. It is likely
that the nuclear localisation of this pool of Nrf2 requires
further increases in ROS levels and/or the contribution
of other factors. For example, the relative activities of
nuclear localisation (NLS) and export signals (NES)
within Nrf2, and the interaction between the transcrip-
tion factor and the importin family of proteins, are
believed to be important determinants of the subcelluar
dynamics of Nrf2 [38,39]. Other factors, including the
direct phosphorylation of Nrf2 [24], may be important.
As such, further work is required to delineate the func-
tional importance of the elevated cytoplasmic levels of
Nrf2 in pancreatic cancer cells.
This study has provided evidence that Nrf2 can regu-
late the rate of proliferation and degree of resistance to
chemotherapeutic agents in pancreatic cancer cells.
Notably, suppression of the Nrf2 target HO-1 using
siRNA has recently been shown to cause a decrease in
proliferation, and an increase in sensitivity to gemcita-
bine, in pancreatic cancer tissue in vitro and in vivo
[40]. Additionally, the efflux transporters BCRP and
MRP5, which were shown here to be regulated by Nrf2
in pancreatic cancer cells, have been implicated in resis-
tance to gemcitabine [32,41,42]. It has been reported
that Nrf2 can be activated by 5FU, possibly as a result
of drug-induced ROS production, in the Keap1-expres-
sing human colon cancer HT-29 cell line [43]. Induction
of Nrf2-regulated cell defence genes is associated with
an increased resistance to 5FU, reversible by Nrf2-
targeting siRNA [43]. We have demonstrated an
increased sensitivity to 5FU following Nrf2 depletion in
FAMPAC cells, although we did not observe a similar
effect in Suit-2 cells that exhibit low levels of Keap1 and
high levels of Nrf2. Interestingly, however, a recent
study has revealed that siRNA depletion of Nrf2 in
TGBC24TKB gall bladder cancer cells, in which Keap1
is not expressed and Nrf2 is constitutively present at
high levels, can increase sensitivity to 5FU [20]. Clearly,
the contribution of Nrf2 to chemotherapeutic drug
resistance may be complicated, and indeed cell type
specific, and further investigations are required to
understand these mechanisms.
Exposure to gamma radiation causes ionization of
water molecules in the cell, and increases the intracellu-
lar production of free radicals. Since Nrf2 is a key regu-
lator of antioxidant defence, it is possible that the
increased sensitivity to gamma radiation of Suit-2 cells
following Nrf2 depletion is a result of the inability to
mount a defence response in a perturbed redox environ-
ment. Indeed, the activity of Nrf2 has recently been
shown to be important for the ability of prostate cancer
c e l l st or e s i s tt h ec y t o t o x i c i t yc a u s e db ye x p o s u r et o
radiation [44]. It may be valuable to further explore the
role of Nrf2 in protecting against radiation-induced cell
damage in pancreatic cancer. Our data, demonstrating
that Nrf2 plays a role in the resistance of pancreatic
cancer cells towards chemotherapeutic interventions,
were generated following continuous exposure of cells
in vitro. Future experiments will address the issue of
short- and long-term exposure to these molecules, in
order to begin to relate this data to clinically-relevant
therapeutic strategies.
Conclusions
The Nrf2/Keap1 system appears to be dysregulated, yet
functional, in certain pancreatic cancer cell lines, and in
primary pancreatic ductal adenocarcinomas. Further-
more, Nrf2 supports cellular proliferation and che-
motherapeutic drug resistance in some of these cells.
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l i n gp a t h w a yh a st h ep o t e n tial to reduce the rate of
growth of primary pancreatic tumors, and render them
more susceptible to attack by chemotherapeutic agents.
Materials and methods
Reagents
DMEM was purchased from Lonza (Wokingham, UK).
RPMI and foetal bovine serum was purchased from
Gibco (Paisley, UK). Cis-diamminedichloroplatinum (cis-
platin), streptomycin, penicillin, propidium iodide,
RNase, RPMI-1640, RIPA buffer, all primers for sequen-
cing and qRTPCR, Sybr green reagent, anti-rabbit horse-
radish peroxidise-conjugated secondary antibody and
rabbit anti-actin primary antibody were purchased from
Sigma (Poole, UK). CellTiter96 aqueous non-radioactive
cell proliferation assay (MTS) and the ImProm-II
Reverse transcription system were purchased from Pro-
mega (Southampton, UK). HotStarTaq reagents and
QIAquick gel extraction kit were from Qiagen (Crawley,
UK). Anti-goat horseradish peroxidise-conjugated sec-
ondary antibody was purchased from Dako (Ely, UK).
Anti-sheep horseradish peroxidise-conjugated secondary
antibody was purchased from Calbiochem (Nottingham,
UK). Enhanced chemiluminescence was purchased from
PerkinElmer (Beaconsfield, UK). Goat anti-Keap1 and
rabbit anti-Nrf2 primary antibodies were purchased
from Santa Cruz (Heidelberg, Germany). siRNA targeted
against Nrf2 was purchased from Dharmacon (Lafayette,
USA). Scrambled med GC RNA negative control, siRNA
targeted against Keap1, TRIzol, Lipofectamine RNAi-
MAX and 4-12% Novex bis-tris polyacrylamide gels
were purchased from Invitrogen (Paisley, UK). Rabbit
anti-AKR1c1 primary antibody was a kind gift from
Prof. John Hayes (University of Dundee, UK). Sheep
anti-GCLC primary antibody was a kind gift from
Dr. Lesley McLellan (University of Dundee, UK).
Cell culture
MiaPaca-2, Panc-1, FAMPAC, Paca-2 and Suit-2 cell
lines were maintained at 37°C in a 5% CO2 atmosphere
in DMEM (MiaPaca-2, Panc-1 and Suit-2) or RPMI-
1640 (FAMPAC and Paca-2), both supplemented with
10% fetal bovine serum, 100 U/mL penicillin and
100 ug/mL streptomycin.
Immunoblotting
Whole cell lysates were obtained by lysing cells in RIPA
buffer. Cell lysates were resolved on pre-cast 4-12%
Novex bis-tris polyacrylamide gels. Separated proteins
were transferred to nitrocellulose membranes, which
were blocked for 30 min using 10% non-fat milk in tris-
buffered saline. Membranes were probed for 24 h with
anti-Nrf2, or for 1 h with anti-Keap1, anti-GCLC, anti-
AKR1c1 or anti-actin primary antibodies. Membranes
were washed and then probed for 1 h with the appropri-
ate HRP-linked secondary antibody. Proteins were visua-
lised by enhanced chemiluminescence using Hyperfilm
ECL.
Quantification of mRNA
Total RNA was extracted using TRIzol following the
manufacturer’s protocol. RNA quality and quantity was
measured using a ND-1000 spectrophotometer (Nano-
drop, Wilmington, USA). cDNA was synthesised using
the ImProm-II Reverse transcription system. cDNA
(50 ng) was analysed using qPCR using primers designed
for Nrf2, HO-1, MRP5, BCRP and GAPDH (Additional
file 9, Table S3) and Sybr green following the manufac-
turer’s protocol. For siRNA-treated cells, GAPDH was
used for normalisation. To measure the copy number of
NRF2/KEAP1 m R N Ap e r5 0n go fc D N A ,s t a n d a r d
curves (0-1,000,000 copies) were constructed from hNrf2
and hKeap1 plasmid expression vectors.
Glutathione assay
Cell lines were grown for 24 h and total cellular glu-
tathione (GSH) content was quantified as previously
described [45].
Sequencing of KEAP1 and NRF2
Genomic DNA from all five pancreatic cancer cell lines
was amplified by PCR using HotStarTaq reagents and
exon-specific primers for KEAP1 and NRF2 (Additional
file 9, Table S3). Products were gel-purified using a
QIAquick gel extraction kit and sequenced (Geneservice,
Cambridge, UK). Sequences were subjected to a BLAST
search against the wild type KEAP1 [NM_012289] and
NRF2 [NM_006164] genomic sequences obtained from
the NCBI database, and verified by manual analysis.
Data relevant to the amplification, deletion and muta-
tion status of KEAP1 and NRF2 was retrieved from the
Jones et al. pancreatic cancer series [26].
Genotyping of pancreatic cancer cell lines
The identities of all the cell lines used in this study were
validated using the following approach: Genotyping was
performed using PowerPlex-16 HS System (Promega)
according to the manufacturer’s instruction manual.
Briefly, genomic DNA was isolated from pancreatic can-
cer cell lines using the Qiagen DNA mini kit. One ng of
DNA was subjected to PCR reaction using PowerPlex-
16 HS System (Promega), in accordance with the manu-
facturer’s instructions. Detection of amplified fragments
was carried out using Genetic Analyser (3130-Applied
Biosystem) and GeneMapper software (Version 4.0).
Lister et al. Molecular Cancer 2011, 10:37
http://www.molecular-cancer.com/content/10/1/37
Page 10 of 13siRNA transfection
MiaPaca-2, FAMPAC and Suit-2 cells were seeded onto
96- and 6-well plates at 5 × 10
4 and 1 × 10
5 cells per
well, respectively, and transfected using lipofectamine
R N A i M A Xw i t h1 0n Mo fs i R N At a r g e t e da g a i n s t
NRF2, KEAP1 or a scrambled RNA negative control.
Cells were transfected for the specified time periods,
depending on the subsequent analysis.
Cell viability and proliferation assays
After 120 h transfection with siRNA molecules, cell via-
bility was measured using the MTS assay. Alternatively,
following siRNA transfection, cells were harvested at 24,
48, 72, 96, and 120 h, and viable cells were counted
using Trypan blue staining.
Analysis of cell cycle and apoptosis
FAMPAC and Suit-2 cells transfected with siRNA for
72 h were harvested, fixed in 70% ethanol solution and
stored at 4°C overnight. Cells were then washed and
treated with RNase (10 mg/ml) for 5 min, followed by
the addition of propidium iodide (1 mg/ml). Cells were
incubated in the dark for 30 min and the cell cycle was
analysed using a Coulter Beckman flow cytometer. Data
were processed using winMDI software. Apoptosis was
measured using the Annexin V:FITC assay kit (AbD
Serotec) according to the manufacturer’s instruction
manual. Briefly, FAMPAC and Suit-2 were transfected
with siRNA for 72 h, stained with Annexin-5 for
10 min, then washed and stained with propidium iodide
as described above. Apoptosis was detected using a
Coulter Beckman flow cytometer.
Chemo- and radiotherapy treatment
Forty-eight hours following siRNA transfection, cells
were treated with the indicated concentrations of gemci-
tabine, 5-flurouracil or cisplatin, or 20 gy of gamma
radiation (Gammacell 1000), for 72 h and cell viability
was measured by MTS assay. Cell viability was
expressed relative to the vehicle control-treated cells.
Immunohistochemistry
Immunohistochemical staining was performed on a pan-
creatic ductal adenocarcinoma tissue microarray (TMA)
containing matched duplicate non-malignant and malig-
nant cores from 63 patients, who had undergone surgical
resection at the Royal Liverpool University Hospital, UK,
between 1994 and 2003. For 21 cancer cases, matching
non-malignant cores contained benign ducts that could be
evaluated. Immunohistochemical staining was performed
as described previously [46], using primary antibodies
directed against Keap1 (1:50 dilution) or Nrf2 (1:200 dilu-
tion). Isotype controls for both Nrf2 and Keap1 staining
were also preformed (Additional file 10, Figure S7).
Scoring and statistical analysis of immunohistochemically-
stained tissue arrays
Scoring of the IHC slides was performed by two inde-
pendent reviewers, one of whom (author Campbell) is a
specialist gastrointestinal histopathologist. The informa-
tion recorded for Nrf2 included the subcellular location
and the intensity of staining (graded 0 = negative; 1 =
weak; 2 = moderate; and 3 = strong) and the extent of
staining (percentage of cells showing positive immunor-
eactivity: 0 - 100% of cells). For Nrf2, a score was
assigned for each cellular compartment = the intensity
of staining X the percentage of cells stained. Negative
cases were defined as having a score of 0, weak cases, a
score between 0 and 50 and strong cases had a score
greater than 50. Keap1 staining was patchy and granular
throughout the tumor. Tumors were therefore scored as
either positive or negative for Keap1. Nrf2 or Keap1
immunohistochemical scores of benign and malignant
cells were compared using the Mann-Whitney U-test.
All statistical analyses were performed using Statview
version 5.01. Further details on associations between
Nrf2/Keap1 and clinicopathologic parameters are
included in Additional file 7 &8, Tables S1 and S2.
Statistical analysis
Data are expressed as the mean ± standard deviation of
at least three independent experiments. The significance
of differences within the data was assessed by one-way
analysis of variance (ANOVA), with Tukey post-test for
multiple comparisons. Student’s paired t-test (para-
metric) or a Mann-Whitney test (non-parametric) was
used for appropriate data sets. P values of < 0.05 were
considered statistically significant.
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Additional material
Additional file 1: Figure S1 - Quantification of Nrf2 and Keap1
mRNA abundance in pancreatic cancer cell lines. cDNA was
synthesised from isolated RNA from five pancreatic cancer cell lines. Nrf2
and Keap1 mRNA levels were quantified by RTPCR using plasmids
containing hNrf2 and hKeap1 cDNA as standards.
Additional file 2: Figure S2 - Immunoblots depicting the area
between 20-100 KDa to demonstrate specificity of antibodies used
in the study. Cells were transfected with 10 nM Nrf2-targeting siRNA, or
Stealth RNAi control, for 96 h in three parallel experiments. A,
Immunoblot detection of Keap1. Beta-actin is used as reference control.
B, Immunoblot detection of GCLC and AKR1c1.
Additional file 3: Figure S3 - Quantification of HO-1, BCRP and
ABCC5 mRNA levels in Suit-2 cells following siRNA depletion of
Nrf2. Cells were transfected with 10 nM Nrf2-targeting siRNA, or Stealth
RNAi control, for 96 h. mRNA levels were quantified by qRTPCR. GAPDH
was used as a reference control. Data are the means ± S.D. of four
discrete experiments. * = P < 0.05, ** = P < 0.01.
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Page 11 of 13Additional file 4: Figure S4 - siRNA depletion of Keap1 in FAMPAC
and Suit-2 cells. Cells were transfected with 10 nM Keap1-targeting
siRNA, or Stealth RNAi control, for 96 h. Immunoblot detection of Keap1,
Nrf2, GCLC and AKR1c1. Beta-actin is used as reference control.
Additional file 5: Figure S5 - Effect of siRNA depletion of Keap1 on
viability of FAMPAC cells. Cells were transfected with 10 nM Keap1-
targeting siRNA, or Stealth RNAi control, for 120 h. Cell survival was
measured using the MTS test. Data is shown as cell viability versus
Stealth RNAi transfected control. *** = P < 0.001.
Additional file 6: Figure S6 - Distribution of Nrf2 staining in the
cytoplasm and nucleus of tumors and matching benign cores.
Histograms showing Nrf2 stained tissues (n = 21 tumor cases and
matched benign tissue) categorised into 4 distinct groups, i.e. those
containing: i) high cytoplasmic Nrf2 and high nuclear Nrf2 (H
C/H
N), ii)
high cytoplasmic Nrf2 and low nuclear Nrf2 (H
C/L
N), iii) low cytoplasmic
Nrf2 and high nuclear Nrf2 (L
C/H
N) and iv) low cytoplasmic Nrf2 and low
nuclear Nrf2 (L
C/L
N).
Additional file 7: Table S1 - Association between Nrf2 levels and
clinicopathologic parameters in pancreatic tumors. Data were
available for all 57 patients, with the exception of perineural invasion (n
= 55), vascular invasion (n = 54) and resection margin status (n = 52).
Additional file 8: Table S2 - Association between Keap1 levels and
clinicopathologic parameters in pancreatic tumors. Data were
available for all 66 patients, with the exception of perineural invasion (n
= 60), vascular invasion (n = 61) and resection margin status (n = 58).
Additional file 9: Table S3 - Oligonucleotide sequences. A and B,
Primers for gene sequencing. C, siRNA molecules. D, Primers for RTPCR
analysis.
Additional file 10: Figure S7 - Isotype controls for Nrf2/Keap1 IHC
staining in pancreatic tumors.
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